MOYOM Biotech has secured a new financing round from Cathay Capital’s Cathay Consumer Co-Creation Fund to accelerate global growth of its regenerative aesthetics portfolio. The investment will support clinical development, regulatory expansion and international commercialization of the company’s biomaterial technologies.
Get the latest in Medical Aesthetics in our weekly ValuraNova Pulse. Sign up now.
MOYOM’s flagship Aphranel® is a next-generation calcium hydroxylapatite (CaHA) biostructurer designed to combine immediate structural support with regenerative stimulation and complete biodegradation. Its platform uses proprietary ACD-MT® CaHA microspheres and PCD-ETT® physically cross-linked CMC gel technology to support tissue interaction and controlled degradation.
Aphranel® received Class III registration from China’s NMPA in 2025 and EU MDR certification in May 2026. Since its commercial launch in May 2025, the product has been introduced across more than 700 medical aesthetics clinics in China, giving MOYOM an established commercial base ahead of international expansion.
The new financing will help MOYOM pursue additional regulatory approvals, clinical translation and overseas market entry, with Cathay Capital’s global consumer, healthcare and technology network supporting the company’s efforts to bring its regenerative biomaterials from China to international aesthetics markets.
Read the full story here.
